NNE

NNE is a pre-revenue, development-stage nuclear microreactor company that, in its own words, has "not generated any revenue since our inception" and does "not expect to generate any revenue unless and until we are able to commercialize our reactors." The 10-K is explicit that investing is "speculative and involves a high degree of risk" and that operating losses and negative cash flows "will increase in the coming years." The numbers confirm the trajectory: the FY2025 net loss widened to -$40.1M from -$10.2M (a 294.7% deterioration), R&D more than quadrupled to $15.4M, and operating cash flow was -$19.6M. Returns are structurally negative (ROE -18.0%) because there is no revenue line to return on — there is nothing to value with P/E, P/S, or any growth-adjusted multiple.

The one genuine strength is the balance sheet. Successive equity raises lifted cash to $203M (+613% YoY) and stockholders' equity to $223M against just $6.09M of total liabilities (liabilities/equity of 0.03x), so near-term solvency is not the concern — the company is essentially debt-free and funded for several years of its planned ~$65M/yr burn. But that strength came at shareholders' expense: shares outstanding grew 37.9% in a single year, and management states it will continue "equity financing from investors to satisfy our funding needs." Holders should expect ongoing dilution on the multi-year path to 2030.